Combination therapy for bile duct cancer in the liver
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is testing a combination of treatments for a specific type of liver cancer (intrahepatic cholangiocarcinoma) that can't be removed surgically. The combination includes a liver-directed chemotherapy infusion, tiny beads that deliver chemo directly to the tumor, an immunotherapy drug (toripalimab), and a targeted therapy pill (lenvatinib). This approach aims to shrink the tumor and control the cancer for as long as possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have a confirmed diagnosis of intrahepatic cholangiocarcinoma (a cancer that starts in the bile ducts inside the liver).
- Your cancer is locally advanced and can't be removed with surgery, but it has not spread to distant organs (except possibly to lymph nodes).
- You have not had certain previous treatments: no prior immunotherapy, chemo, or targeted therapy.
- Your liver function is good (scored as Child-Pugh A or mild B), and you are physically able to care for yourself (ECOG 0-1).
- You do not have active autoimmune disease or significant fluid buildup in your belly (ascites).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of liver-directed therapy (D-TACE-HAIC), an immunotherapy drug (Envafolimab), and a targeted therapy pill (Lenvatinib) for people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. The goal is to see if this combination can shrink or control the cancer.
This trial tests a combination of targeted therapy, immunotherapy, and a liver-directed procedure (like chemoembolization) versus a standard chemotherapy cocktail for a type of bile duct cancer that is confined to the liver. It aims to see if the new combo can help patients live longer or slow the cancer down.
This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.
This trial tests a combination of three drugs for bile duct cancer that cannot be removed by surgery: sintilimab (an immunotherapy that helps your immune system fight cancer), bevacizumab (a drug that blocks blood vessel growth to tumors), and a standard chemotherapy called AG (gemcitabine and capecitabine). The goal is to see if this combination can help shrink or control the cancer as a first treatment option.
This trial tests a combination treatment for biliary tract cancer that is borderline resectable or locally advanced. It combines a chemotherapy infusions directly into the liver (HAIC) with an immunotherapy drug (adebrelimab) and a targeted therapy pill (lenvatinib), aiming to shrink the tumor enough to allow surgery.
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) with the targeted therapy lenvatinib and the immunotherapy adebrelimab for people with advanced bile duct cancer that cannot be removed by surgery. It aims to see if this combination works better than standard treatments.
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.